ALVIO — Valerio Therapeutics SA Share Price
Last trade - 00:00- €10.01m
- €19.19m
- €1.80m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.49 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 5.3 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -99.89% | ||
| Return on Equity | -144.55% | ||
| Operating Margin | -1038.64% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | €m | 4.29 | 1.78 | 4.06 | 1.44 | 1.8 | n/a | n/a | -21.73% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Valerio Therapeutics SA formerly Onxeo SA is a France-based clinical-stage biotechnology company. The company targets tumor DNA functions through unparalleled mechanisms of action in the sought-after field of DNA damage response (DDR). It aims at holding a portfolio of advanced programs targeting severe pathologies with unmet clinical needs. It has two programs in clinical development stage: Livatag, a doxorubicin Transdrag in Phase III, for the treatment of primary liver cancer, and Validive, a clonidine Lauriad in Phase II, for treatment of radio/chemo-induced severe oral mucositis at patients with head and neck cancer. It also has one registered product in the United States, Beleodaq/ belinostat, for the treatment of peripheral T-Cell lymphoma (PTCL) and opportunities for further development; and two initial drugs registered in Europe and the United States: Loramyc/ Oravig for the treatment of oropharyngeal candidiasis, and Sitavig for the treatment of recurring herpes labialis.
Directors
- Shefali Agarwal CHM (47)
- Julien Miara CEO
- Nicolas Fellman CFO (50)
- Olivier De Beaumont EXB
- Christine Garnier DRC (60)
- Nicolas Trebouta DRC (58)
- Jean-pierre Bizarri IND
- Robert Coleman IND
- Daniele Guyot - Caparros IND
- Thomas Hofstaetter IND (74)
- Jacques Mallet IND (61)
- Last Annual
- December 31st, 2023
- Last Interim
- June 30th, 2024
- Incorporated
- February 3rd, 1997
- Public Since
- July 12th, 2005
- No. of Employees
- 38
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Euronext - Paris
- Shares in Issue
- 153,971,908
- Address
- 49 boulevard du General Martial Valin, PARIS, 75015
- Web
- https://www.onxeo.com/
- Phone
- +33 145587600
- Auditors
- Aca Nexia
Upcoming Events for ALVIO
Similar to ALVIO
AB Science SA
Euronext - Paris
Advicenne SA
Euronext - Paris
Aelis Farma SA
Euronext - Paris
Boiron SA
Euronext - Paris
DBV Technologies SA
Euronext - Paris
FAQ
As of Today at 23:55 UTC, shares in Valerio Therapeutics SA are trading at €0.07. This share price information is delayed by 15 minutes.
Shares in Valerio Therapeutics SA last closed at €0.07 and the price had moved by -42.48% over the past 365 days. In terms of relative price strength the Valerio Therapeutics SA share price has underperformed the FTSE Global All Cap Index by -43.92% over the past year.
The overall consensus recommendation for Valerio Therapeutics SA is Strong Sell. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreValerio Therapeutics SA does not currently pay a dividend.
Valerio Therapeutics SA does not currently pay a dividend.
Valerio Therapeutics SA does not currently pay a dividend.
To buy shares in Valerio Therapeutics SA you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of €0.07, shares in Valerio Therapeutics SA had a market capitalisation of €10.01m.
Here are the trading details for Valerio Therapeutics SA:
- Country of listing: France
- Exchange: PAR
- Ticker Symbol: ALVIO
Based on an overall assessment of its quality, value and momentum Valerio Therapeutics SA is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Valerio Therapeutics SA. Over the past six months, its share price has underperformed the FTSE Global All Cap Index by -21.5%.
As of the last closing price of €0.07, shares in Valerio Therapeutics SA were trading -14.73% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Valerio Therapeutics SA PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at €0.07.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Valerio Therapeutics SA's management team is headed by:
- Shefali Agarwal - CHM
- Julien Miara - CEO
- Nicolas Fellman - CFO
- Olivier De Beaumont - EXB
- Christine Garnier - DRC
- Nicolas Trebouta - DRC
- Jean-pierre Bizarri - IND
- Robert Coleman - IND
- Daniele Guyot - Caparros - IND
- Thomas Hofstaetter - IND
- Jacques Mallet - IND